Sopharma Trading AD (XBUL:SFT) EBIT: €38 Mil (TTM As of Mar. 2026)


XBUL:SFT Sopharma Trading AD XBUL:SFT
84 GF Score
Price €2.92
GF Value €7.60
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD EBIT?

Sopharma Trading AD XBUL:SFT -0.68% 84 EBIT is €38 Mil as of Mar. 2026. GuruFocus rates XBUL:SFT with a GF Score™ of 84/100 and a GF Value™ of €7.60 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Sopharma Trading AD's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €38 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sopharma Trading AD's annualized ROC % for the quarter that ended in Mar. 2026 was 13.88%. Sopharma Trading AD's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sopharma Trading AD's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.98%.


Sopharma Trading AD  (XBUL:SFT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sopharma Trading AD's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=45.32 * ( 1 - 6.29% )/( (301.33 + 310.755)/ 2 )
=42.469372/306.0425
=13.88 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sopharma Trading AD's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=42.42/( ( (80.888 + max(127.729, 0)) + (81.918 + max(141.524, 0)) )/ 2 )
=42.42/( ( 208.617 + 223.442 )/ 2 )
=42.42/216.0295
=19.64 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(121.899 + 182.425 + 3.936) - (168.529 + 0 + 12.002)
=127.729

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(133.737 + 182.261 + 4.0000000000001) - (165.908 + 0 + 12.566)
=141.524

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sopharma Trading AD's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=37.735/270.004
=13.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sopharma Trading AD EBIT Related Terms


Sopharma Trading AD EBIT Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD EBIT Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.54 8.90 21.69 28.91 41.98

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.85 11.49 8.56 7.08 10.61

XBUL:SFT vs MCK, CAH, COR: EBIT Comparison

For the Medical Distribution subindustry, Sopharma Trading AD's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma Trading AD EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sopharma Trading AD's EV-to-EBIT falls into.


XBUL:SFT
84GF Score
Sopharma Trading AD XBUL:SFT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €38 Mil mean?
Sopharma Trading AD (XBUL:SFT) has a EBIT of €38 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sopharma Trading AD.
Is Sopharma Trading AD's EBIT too high?
Sopharma Trading AD's current EBIT is €38 Mil. Overall, Sopharma Trading AD has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's EBIT compare to MCK and CAH?
Sopharma Trading AD's EBIT of €38 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sopharma Trading AD. Sopharma Trading AD's current EBIT is €38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.60, compared to a current price of €2.92 — trading 61.6% below its estimated fair value. The current EBIT is €38 Mil. Sopharma Trading AD's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current EBIT is €38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €2.92 is trading 61.6% below its estimated GF Value™ of €7.60. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • EBIT: €38 Mil
  • GF Value™: €7.60 vs. price of €2.92 (61.6% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
84GF Score

Get the complete analysis for XBUL:SFT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price
€7.60
GF Value